PATHOGENESIS, CLINICAL AND LABORATORY FEATURES OF CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
https://doi.org/10.24884/1607-4181-2018-25-3-14-24
Abstract
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired progressive or relapse-remitting immunemediated disease of peripheral nervous system. CIDP has typical and atypical variants. Typical variant includes development of symmetric motor and sensory nerve fibers functions abnormalities. The diagnosis of CIDP reveals on clinical presentation and electrophysiological data. There aren’t any biomarkers of such disease. Cerebrospinal fluid analysis, magnetic resonance tomography of peripheral nerves and nerve biopsy may be additional methods to confirm the diagnosis. Instead of international criteria of CIDP diagnosis and large variety of laboratory and instrumental methods, there are many difficulties to make the appropriate diagnosis. This review discusses current concepts of pathogenesis, clinical diagnostics and laboratory and instrumental methods used for differential diagnosis and confirmation of the diagnosis of CIDP and new areas in CIDP research.
About the Authors
R. A. Gapeshin
Pavlov University.
Russian Federation
6-8 L’va Tolstogo street, Saint-Petersburg, Russia, 197022.
Russian Federation
6-8 L’va Tolstogo street, Saint-Petersburg, Russia, 197022.
E. R. Barantsevich
Pavlov University.
Russian Federation
6-8 L’va Tolstogo street, Saint-Petersburg, Russia, 197022.
Russian Federation
6-8 L’va Tolstogo street, Saint-Petersburg, Russia, 197022.
A. A. Yakovlev
Pavlov University; Federal State Budgetary Educational Institution of Higher Education «North-Western State Medical University named after I. I. Mechnikov».
Russian Federation
6-8 L’va Tolstogo street, Saint-Petersburg, Russia, 197022.
Russian Federation
6-8 L’va Tolstogo street, Saint-Petersburg, Russia, 197022.
References
1. Bril V, Blanchette CM, Noone JM, Runken MC, Gelinas D, Russell JW. The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy. J Diabetes Complications. The Authors; 2016;30(7):1401-7. Available from: http://dx.doi.org/10.1016/jjdiacomp.2016.05.007
2. Nobile-orazio E. 2013 PERIPHERAL NERVE SOCIETY MEETING PNS PRESIDENTIAL LECTURE Chronic inflam-matory demyelinating polyradiculoneuropathy and variants : where we are and where we should go Clinical Presentation : One or More. J Peripher Nerv Syst. 2014;13:2-13.
3. Tursynov NI, Grigolashvili MA, Iluyshina NYu et al. Modern aspects of diagnosis and treatment of chronic demyelinated polyneuropathies. Neurosurgery and Neurology of Kazahstan. 2016;3(44):38-45. (In Russian)
4. Schafflick D, Kieseier BC, Wiendl H, Meyer zu Horste G. Novel pathomechanisms in inflammatory neuropathies. J Neuroinflammation. Journal of Neuroinflammation; 2017; 14(1):1—17.
5. Popova TE, Shnayder NA, Petrova MM et al. Diagnosis of postural disorders in patients with sensory chronic poly-neuropathies: a pilot research. Syberian Medical Review. 2015;3:42-7. (In Russian)
6. Melzer N, Meuth SG. Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: Common and divergent current and future strategies. Clin Exp Immunol. 2014;175(3):359-72.
7. Spies JM, Westland KW, Bonner JG, Pollard JD. Intraneural activated t cells cause focal breakdown of the blood-nerve barrier. Brain. 1995;118(4):857-68.
8. Svahn J, Antoine JC, Camdessanche JP Pathophy¬siology and biomarkers in chronic inflammatory demyeli- nating polyradiculoneuropathies. Rev Neurol (Paris). 2014; 170(12):808-17.
9. Tackenberg B, Jelcic I, Baerenwaldt A, Oertel WH, Sommer N, Nimmerjahn F, et al. Impaired inhibitory Fc receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci. 2009; 106(12):4788-92. Available from: http://www.pnas.org/cgi/ doi/10.1073/pnas.0807319106
10. Beppu M, Sawai S, Satoh M, Mori M, Kazami T, Misawa S, et al. Autoantibodies against vinculin in patients with chronic inflammatory demyelinating polyneuro¬pathy. J Neuroimmunol. Elsevier B.V; 2015; 287:9-15. Available from: http://dx.doi.org/10.1016/jjneuroim.2015. 07.012
11. Weiner J a, Fukushima N, Contos JJ, Scherer SS, Chun J. Regulation of Schwann cell morphology and adhesion by receptor-mediated lysophosphatidic acid signaling. J Neurosci. 2001;21(18):7069-78.
12. Devaux J, Yumako M, Yumako F, Takayuki I, Cons¬tance M, Maya B, et al. Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy. Neurology. 2016;86:800-7.
13. Querol L, Nogales-Gadea G, Rojas-Garcia R, Martinez- Hernandez E, Diaz-Manera J, Suarez-Calvet X, et al. Antibodies to contactin-1 in chronic inflammatory demyelinating poly¬neuropathy. Ann Neurol. 2013;73(3):370-80.
14. Ogawa-Goto K, Funamoto N, Ohta Y, Abe T, Naga- shima K. Myelin Gangliosides of Human Peripheral Nervous System: An Enrichment of GM1 in the Motor Nerve Myelin Isolated from Cauda Equina. J Neurochem. 1992;59(5):1844-9.
15. Uncini A, Susuki K, Yuki N. Nodo-paranodopathy: Beyond the demyelinating and axonal classification in anti- ganglioside antibody-mediated neuropathies. Clin Neuro¬physiol. International Federation of Clinical Neurophysio¬logy; 2013;124(10):1928-34. Available from: http://dx.doi. org/10.1016/j.clinph.2013.03.025
16. Kuwahara M, Suzuki S, Takada K, Kusunoki S. Anti-bodies to LM1 and LM1-containing ganglioside complexes in Guillain-Barré syndrome and chronic inflammatory de- myelinating polyneuropathy. J Neuroimmunol. Elsevier B. V ; 2011;239(1-2):87-90. Available from: http://dx.doi.org/ 10.1016/j.jneuroim.20n.08.016
17. Vedeler CA, Farbu E, Mellgren SI. Chronic inflam¬matory demyelinating polyneuropathy (CIDP). Acta Neurol Scand. 2013;127:48-51. Available from: http://doi.wiley. com/10.1111/ane.12049
18. Mathey EK, Park SB, Hughes RAC, Pollard JD, Armati PJ, Barnett MH, et al. Chronic inflammatory demy¬elinating polyradiculoneuropathy: from pathology to phe¬notype. J Neurol Neurosurg Psychiatry [Internet]. 2015; 86(9):973-85. Available from: http://jnnp.bmj.com/lookup/ doi/10.1136/jnnp-2014-309697
19. Cao Y, Menon P, Ching-Fen Chang F. et al. Postural Tremor and Chronic Inflammatory Demyelinating Polyneuropathy // Musle & Nerve. - 2016. - №> 55 (3). - P 338-343. Doi: 10.1002/mus.25253.
20. Abraham A, Albulaihe H, Alabdali M, Qrimli M, Breiner A, Barnett C, et al. Elevated vibration perception thresholds in CIDP patients indicate more severe neuropathy and lower treatment response rates. PLoS One. 2015;10(11):1-9.
21. Hickman SJ, Allen JA, Baisre A, Batty R, Lari HB, Melen O, et al. Neuro-ophthalmological complications of chronic inflammatory demyelinating polyradiculoneuropathy. Neuro-Ophthalmology. 2013;37(4):146-56.
22. Al-Bustani N, Weiss MD. Recurrent Isolated Sixth Nerve Palsy in Relapsing-Remitting Chronic Inflammatory Demyelinating Polyneuropathy. J Clin Neuromuscul Dis. 2015;17(1):18-21.
23. Figueroa JJ, Dyck PJB, Laughlin RS, Mercado JA, Massie R, Sandroni P, et al. Autonomic dysfunction in chronic inflammatory demyelinating polyradiculoneuropathy. Neuro¬logy. 2012;78(10):702-8. Available from: http://www.neurology. org/cgi/doi/10.1212/WNL.0b013e3182494d66
24. Liu LY, Mao WC, Tai YM, Chang HA, Kao YC, Yeh C Bin, et al. Chronic inflammatory demyelinating polyneuro¬pathy associated with manic symptoms. Aust N Z J Psychiatry. 2017;51(6):641.
25. Abraham A, Albulaihe H, Alabdali M, Qrimli M, Breiner A, Barnett C, et al. Frequent laboratory abnormalities in CIDP patients. Muscle and Nerve. 2016;53(6):862-5.
26. Vina ER, Fang AJ, Wallace DJ, Weisman MH. Chronic inflammatory demyelinating polyneuropathy in patients with systemic lupus erythematosus: Prognosis and outcome. Semin Arthritis Rheum. 2005;35(3):175-84.
27. Zoilo MA, Eduardo B, Enrique F, del Rocio MVM. Chronic inflammatory demyelinating polyradiculoneuropathy in a boy with systemic lupus erythematosus. Rheumatol Int. 2010;30(7):965-8. Available from: http://www.ncbi.nlm.nih. gov/pubmed/19536546
28. Federal Clinical Recommendations for treatment chil¬dren sufferinf from chronic demyelinating polyneuropathy. Union of russianpediatrics. 2013;1—12.
29. Van den Bergh PYK, Hadden RDM, Bouche P, Corn- blath DR, Hahn A, Illa I, et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripher. Eur J Neurol. 2010;17(3):356-63. Available from: http://doi.wiley.com/10.1111/j.1468-1331. 2009.02930.x
30. Breiner A, Brannagan TH. Comparison of sensitivity and specificity among 15 criteria for chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2014;50(1):40- 6. Available from: http://doi.wiley.com/ 10.1002/mus.24088
31. Koski CL, Baumgarten M, Magder LS, Barohn RJ, Goldstein J, Graves M, et al. Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. Elsevier B.V; 2009; 277(1-2): 1-8. Available from: http://dx.doi.org/10.1016/jjns.2008. 11.015
32. Allen JA, Lewis RA. CIDP diagnostic pitfalls and per-ception of treatment benefit. Neurology. 2015;85(6):498-504.
33. Allen JA, Gorson KC, Gelinas D. Challenges in the diagnosis of chronic inflammatory demyelinating poly¬neuropathy. BrainBehav [Internet]. 2018;8(3):e00932. Avai¬lable from: http://doi.wiley.com/10.1002/brb3.932
34. Prietl B, Pilz S, Wolf M, Tomaschitz A, Obermayer¬Pietsch B, Graninger W, et al. Vitamin D supplementation and regulatory T cells in apparently healthy subjects: vitamin D treatment for autoimmune diseases? Isr Med Assoc J. 2010;12(march):136-9.
35. Elf K, Askmark H, Nygren I, Punga AR. Vitamin D deficiency in patients with primary immune-mediated peripheral neuropathies. J Neurol Sci. Elsevier B.V; 2014; 345(1):184-8. Available from: http://dx.doi.org/10.1016Zj. jns.2014.07.040
36. Bonin S, Zanotta N, Sartori A, Bratina A, Manganotti P, Trevisan G, et al. Cerebrospinal Fluid Cytokine Expression Profile in Multiple Sclerosis and Chronic Inflammatory Demyelinating Polyneuropathy. Immunol Invest. Taylor & Francis; 2018;47(2):135-45. Available from: https://doi.org/ 10.1080/08820139.2017.1405978
37. Tumani H, Pfeifle M, Lehmensiek V, Rau D, Mogel H, Ludolph AC, et al. Candidate biomarkers of chro¬nic inflammatory demyelinating polyneuropathy (CIDP): Proteome analysis of cerebrospinal fluid. J Neuroimmunol. 2009;214(1-2):109-12.
38. Rentzos M, Angeli A V, Rombos A, Kyrozis A, Nikolaou C, Zouvelou V, et al. Proinflammatory cytokines in serum and cerebrospinal fluid of CIDP patients. Neurol Res. 2012;34(9):842-6. Available from: http://www.tandfonline. com/doi/full/10.1179/1743132812Y.0000000074
39. Lin KY, Wang IH, Jou JR, Chu HJ, Wei W, Lee SH, et al. Bilateral optic neuritis related to chronic inflammatory demyelinating polyneuropathy. Taiwan J Ophthalmol. Else¬vier Taiwan LLC; 2015;5(1):40-3. Available from: http:// dx.doi.org/10.1016/j.tjo.2014.04.002
40. Cortese A, Franciotta D, Alfonsi E, Visigalli N, Zardini E, Diamanti L, et al. Combined central and peripheral demyelination: Clinical features, diagnostic findings, and treatment. J Neurol Sci. Elsevier B. V; 2016; 363:182-7. Available from: http://dx.doi.org/10.1016/j. jns.2016.02.022
41. Bouchard C, Lacroix C, Planté V, Adams D, Chedru F, Guglielmi JM, et al. Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy. Neurology. 1999;52(3):498-503.
42. Feasby TE, al. et. Central lesions in chronic inflam¬matory demyelinating polyneuropathy: An MRI study. 1990; 40(March):476-8.
43. Laura M, Leong W, Murray NMF, Ingle G, Miszkiel KA, Altmann DR, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: MRI study of brain and spinal cord. Neurology. 2005;64(5):914-6. Available from: http://www. neurology. org/lookup/doi/10.1212/01.WNL. 0000152842.11864.D0
44. Ioannidis P, Parissis D, Karapanayiotides T, Maiovis P, Karacostas D, Grigoriadis N. Spinal cord involvement in chronic inflammatory demyelinating polyradiculoneuropathy: a clinical and MRI study. Acta Neurol Belg. 2015;115(2):141 —5.
45. Grooters GS, Tijssen CC, Visser LH. Remarkable hypertrophic hyperechogenic polyneuropathy in a patient with chronic inflammatory demyelinating polyneuropathy. Clin Neurophysiol. International Federation of Clinical Neuro-physiology; 2013;124(7):1483-4. Available from: http:// dx.doi.org/10.1016/j.clinph.2013.01.002
46. Shibuya K, Sugiyama A, Ito S, Misawa S, Sekiguchi Y, Mitsuma S, et al. Reconstruction magnetic resonance neurography in chronic inflammatory demyelinating poly¬neuropathy. Ann Neurol. 2015;77(2):333-7. Available from: http://doi.wiley.com/10.1002/ana.24314
47. Kronlage M, Bäumer P, Pitarokoili K, Schwarz D, Schwehr V, Godel T, et al. Large coverage MR neurography in CIDP: diagnostic accuracy and electrophysiological cor¬relation. JNeurol. 2017;264(7):1434-43.
48. Lozeron P, Lacour MC, Vandendries C, Théaudin M, Cauquil C, Denier C, et al. Contribution of plexus MRI in the diagnosis of atypical chronic inflammatory demyelinating polyneuropathies. J NeurolSci. Elsevier B.V; 2016;360:170- 5. Available from: http://dx.doi.org/10.1016/j.jns.2015.11.048
49. Lichtenstein T, Sprenger A, Weiss K, Slebocki K, Cer-vantes B, Karampinos D, et al. MRI biomarkers of proximal nerve injury in CIDP. Ann Clin TranslNeurol. 2018;5(1):19-28.
50. Sinclair CDJ, Miranda MA, Cowley P, Morrow JM, Davagnanam I, Mehta H, et al. MRI shows increased sciatic nerve cross sectional area in inherited and inflam¬matory neuropathies. J Neurol Neurosurg Psychiatry. 2011; 82(11):1283-6.
51. Mathys C, Aissa J, Zu Hörste GM, Reichelt DC, Antoch G, Turowski B, et al. Peripheral Neuropathy: Asses- sment of Proximal Nerve Integrity By Diffusion Tensor Imaging. Muscle Nerve. 2013;48(6):889-96. Available from: http://doi.wiley.com/10.1002/mus.23855
52. Sommer C, Koch S, Lammens M, Gabreels-Festen A, Stoll G, Toyka K V Macrophage clustering as a diagnostic marker in sural nerve biopsies of patients with CIDP. Neurology. 2005;65(12):1924-9.
53. Üfeyler N, Necula G, Wagemann E, Toyka K V, Sommer C. Endoneurial edema in sural nerve may indicate recent onset inflammatory neuropathy. Muscle and Nerve. 2016;53(5):705-10.
54. Goedee HS, Van Der Pol WL, Van Asseldonk JTH, Franssen H, Notermans NC, Vrancken AJFE, et al. Diagnostic value of sonography in treatment-naive chronic inflammatory neuropathies. Neurology. 2017;88(2):143-51.
55. Kerasnoudis A, Pitarokoili K, Gold R, Yoon MS. Bochum ultrasound score allows distinction of chronic inflammatory from multifocal acquired demyelinating polyneuropathies. J Neurol Sci. Elsevier B.V; 2015;348(1-2):211-5. Available from: http://dx.doi.org/10.l016/j.jns.2014.12.010
56. Ohyama K, Koike H, Katsuno M, Takahashi M, Hashi-moto R, Kawagashira Y, et al. Muscle atrophy in chronic inflammatory demyelinating polyneuropathy: A computed tomography assessment. Eur J Neurol. 2.0l4;21(7):1002—10.
57. Schneider C, Bucher F, Cursiefen C, Fink GR, Heindl LM, Lehmann HC. Corneal confocal microscopy detects small fiber damage in chronic inflammatory demyeli¬nating polyneuropathy (CIDP). J Peripher Nerv Syst. 2014; 19(4):322-7.
58. Stettner M, Hinrichs L, Guthoff R, Bairov S, Petro- poulos IN, Warnke C, et al. Corneal confocal microscopy in chronic inflammatory demyelinating polyneuropathy. Ann Clin Transl Neurol. 2016;3(2):88—100.
Review
For citations:
Gapeshin R.A., Barantsevich E.R., Yakovlev A.A. PATHOGENESIS, CLINICAL AND LABORATORY FEATURES OF CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY. The Scientific Notes of the Pavlov University. 2018;25(3):14-24. (In Russ.) https://doi.org/10.24884/1607-4181-2018-25-3-14-24
Views:
2405
Email this article 